Adaptive Biotechnologies outlined a strategic shift to separate its immune medicine business and re-center on minimal residual disease (MRD) operations. The company also said it expects to offer senior notes to raise as much as $287.5 million, with additional details planned by the end of the year. The restructuring aims to evaluate strategic and structural alternatives for the medicine wing while preserving momentum in MRD, where Adaptive has been building out platforms for detection and monitoring. Management framed the actions as part of a recalibration focused on “MRD business” priorities. For investors and pipeline planners, the financing and separation can affect partnership capacity, operational focus, and the pace at which Adaptive brings MRD-related programs forward amid ongoing market volatility for commercial-stage platforms.